APIs and Excipients

Generate Life Sciences Establishes Newborn Stem Cell Manufacturing Facility

July 16, 2021

The GMP facility is designed to maximize bioprocessing efficiency of newborn stem cells and manufacturing at scale.

Continuus Pharmaceuticals Opens Process Development Lab

July 16, 2021

The new lab near Continuus Pharmaceutical’s current facilities in Massachusetts will expand the company’s process development capabilities to high-potency drugs.

SPI Pharma Introduces Platform for Orally Disintegrating Tablets

July 12, 2021

UltraBurst has a high disintegration speed, which is for all market segments, from prescriptions to nutraceuticals.

GSK and Alector Collaborate on Neurodegenerative Disease mAb Candidates

July 09, 2021

GlaxoSmithKline and Alector have partnered to co-develop two mAbs for a range of neurodegenerative diseases, including Parkinson’s and Alzheimer’s disease.

Complex Biomolecules Require Analytical Evolution

July 03, 2021

The ever-increasing complexity of biotherapeutic molecules presents unique analytical challenges for developers.

Meeting Future Analytical Requirements for Novel Biotherapeutics

July 03, 2021

The future pipeline of complex novel biotherapeutics will require new approaches to analytical assessment.

Subunit Vaccines and the Fight Against COVID-19

July 03, 2021

Advances in technology are accelerating the development and manufacture of subunit vaccines, an established class of vaccines.

Formulating Tablets Layer by Layer

July 03, 2021

Bi-layer tablets are an under-utilized option that can be employed to help reduce treatment burden, but their formulation is more complex than for conventional monolayer products.

Selexis and KBI Biopharma Partner with Immatics to Advance T-Cell Bispecific Program

July 01, 2021

Selexis and KBI Biopharma will use integrated services to advance Immatics’ TCR bispecifics drug development program to the IND stage.

Corbus Pharmaceuticals Expands Pipeline with Two New mAbs

June 30, 2021

Corbus Pharmaceuticals has licensed two integrin-targeting mAbs, expanding its therapeutics pipeline into inflammatory, fibrotic, and metabolic diseases as well as cancer.